U.S.-based biopharmaceutical company has discovered and patented a novelmolecular pathway intended to treat metastatic bone lesions

美国生物制药公司发现并获得了一种治疗转移性骨病变的新分子途径的专利。

Series A Funding will be used for scientific infrastructure to prepare for initial human clinical study

A轮融资将用于科学基础设施，为最初的人类临床研究做准备。

Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

公司知识产权管线靶向针对骨骼相关事件（SRE）和其他肿瘤学治疗以及骨科干预措施。

February 6, 2020, (Syracuse, New York) –

2020年2月6日，（纽约州锡拉丘兹）——

Zetagen Therapeutics, Inc.

泽塔根治疗公司

, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced the close of $5.34M Series A funding round. The financing will accelerate the growth of the Company’s ongoing clinical programs for ZetaMet™ (Zeta-BC-003), a synthetic, small-molecule, inductive biologic being developed to target and resolve metastatic lesions while inhibiting future tumor growth..

一家私人临床阶段的生物制药公司，致力于推动转移性骨癌治疗和骨骼干预的突破性创新，今天宣布完成了534万美元的A轮融资。这笔资金将加速公司正在进行的ZetaMet™（Zeta-BC-003）临床项目的进展，这是一种正在开发中的合成小分子诱导生物制品，旨在靶向并消除转移性病灶，同时抑制未来肿瘤生长。

Read More

READ_MORE